Interim results presented by LegoChem Biosciences at the Working Group on New Drugs Annual Meeting in The Hague October 24, 2018. A new group is being added at 1200 mg QD.
Trial
A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial to Evaluate the EBA, Safety and PK of Orally Administered LCB01-0371 in Adult Patients With Smear-positive Pulmonary Tuberculosis
Overview
Registry Link
Developer Associations
Compound Associations